Welcome to our dedicated page for Inspira Tech SEC filings (Ticker: IINNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Inspira Technologies Oxy B.H.N. Ltd. (IINNW) provides access to the company’s regulatory disclosures as a foreign private issuer. Inspira files annual reports on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934. These filings often include or reference press releases that describe product milestones, regulatory clearances, purchase orders, government-related discussions, and financing transactions.
Through its Form 6-K submissions, Inspira reports developments such as FDA 510(k) clearance and Israeli AMAR certification for the INSPIRA ART100 cardiopulmonary bypass system, government and institutional purchase orders for ART100 systems, and updates on the HYLA real-time blood sensor’s progress toward U.S. Food and Drug Administration submission. Other 6-K filings have covered matters like sales agreement amendments, private placements, and the activation of consulting firms to support business initiatives.
On this page, users can review how Inspira describes its INSPIRA ART platform, ART100 system, VORTX oxygenation technology, INSPIRA Cardi-ART device, and HYLA blood sensor within official filings. These documents outline the development status of each technology, including statements that certain products are still being designed and developed, have not been tested or used in humans, and are not yet approved by regulatory entities.
Stock Titan enhances access to these filings with tools that surface key sections and context from lengthy reports, helping readers quickly locate information on topics such as product regulatory status, capital raising activities, and material agreements. Real-time updates from EDGAR ensure that new Inspira Technologies filings, including future 6-Ks and other forms, appear here as they are submitted, alongside any disclosed information on warrants, purchase orders, or other corporate actions.
Inspira Technologies OXY B.H.N. Ltd. is pivoting into the quantum computing sector, redirecting its recently acquired additive manufactured electronics (AME) platform to solve connectivity bottlenecks inside dilution cryostats. The AME technology, developed with over $200 million of investment, has already shown proof of concept in qubit device integration.
The shift is led by CEO Dagi Ben‑Noon and COO Avi Shabtay, who originally developed the AME technology and previously worked at Nano Dimension, alongside other former Nano Dimension personnel. Inspira plans to keep advancing its INSPIRA ART100 respiratory system and HYLA blood monitoring system under a dedicated medical unit.
The company intends to seek shareholder approval to change its name to QTREX Ltd. and has launched a QTREX website to reflect its focus on quantum connectivity solutions, while continuing commercial discussions in both quantum and medical markets.
Inspira Technologies Oxy B.H.N. Ltd. entered an Asset Purchase Agreement to acquire Nano Dimension Technologies Ltd.’s additive manufacturing electronics and Fabrica businesses, including intellectual property, equipment, inventory, customer contracts and facilities.
The total consideration is up to $12.5 million, with $2.0 million paid in cash at closing and up to $10.5 million in deferred payments over the 12 months following closing, tied to net cash proceeds generated by the acquired platform. Inspira plans to place its existing medical business into a wholly owned subsidiary, which will continue operating independently and is not being sold or discontinued as part of this transaction.
Inspira Technologies Oxy B.H.N. Ltd. submitted a report describing the termination of two equity financing arrangements: its sales agreement with A.G.P./Alliance Global Partners and its Standby Equity Purchase Agreement with YA II PN, Ltd. The company states that no obligations remain and no further advances will be made under either facility. Management explains that ending these facilities aligns with its goal of maintaining a disciplined capital structure as it prepares for its next strategic phase.
The report also highlights that Inspira is a commercial-stage medical device company focused on advanced respiratory support and blood monitoring, including its FDA-cleared INSPIRA ART100 system for cardiopulmonary bypass in the U.S., ECMO-related uses outside the U.S., and development of the INSPIRA ART500 and HYLA blood sensor platform.
Inspira Technologies reported its full-year 2025 results, showing initial commercialization with revenues of about $289,000 from the INSPIRA ART100 system and a net loss of $13.22 million. Operating expenses rose to $13.62 million, driven mainly by higher research and development and general and administrative costs.
Cash, cash equivalents and deposits totaled $3.16 million as of December 31, 2025, with a subsequent registered direct offering adding approximately $4.75 million in gross proceeds. The company also raised about $4.25 million in a separate securities sale and reclassified certain warrants as equity, and believes it now meets Nasdaq’s $2.5 million shareholders’ equity requirement. Inspira terminated its proposed acquisition of Bio-View Ltd.’s liquid biopsy business and is evaluating other strategic alternatives while continuing clinical and early commercial deployment of the ART100 and development of HYLA.
Inspira Technologies Oxy B.H.N. Ltd. files its annual Form 20-F, outlining its respiratory-focused medical device business and key risks. The company develops the INSPIRA ART blood-oxygenation platform, FDA-cleared INSPIRA ART100 cardiopulmonary bypass system, and HYLA real-time blood sensor targeting ICU and surgical settings.
The report highlights intense competition from large global medtech companies, dependence on distributors, supply-chain and cybersecurity risks, and heavy regulatory oversight in the U.S., EU and other markets. Inspira reports an accumulated deficit of about $80 million as of December 31, 2025, ongoing operating losses, limited cash resources, and substantial doubt about its ability to continue as a going concern.
The company notes it had approximately $3.1 million in cash, cash equivalents and deposits and working capital of about $1.6 million at December 31, 2025, which it expects will fund operations for roughly six months. Inspira also discloses Nasdaq minimum-bid-price deficiencies in March 2025 and February 2026, regaining compliance once but again facing a deadline of August 10, 2026 to restore its share price to at least $1.00 to avoid potential delisting.
Inspira Technologies Oxy B.H.N. Ltd. has established a wholly owned subsidiary as part of a revised corporate structure. The company plans to transfer its existing medical business activities into this new entity, concentrating its operating business under the subsidiary.
The report is also incorporated by reference into Inspira Technologies’ existing Form F-3 and Form S-8 registration statements, so that these U.S. securities filings reflect the updated corporate structure from the date of this report.
Inspira Technologies OXY B.H.N. Ltd executive Shabtay Abraham, the COO and VP of R&D, filed an initial ownership report showing his equity position in the company. He directly holds 1,332,713 ordinary shares, plus employee share options over 57,144 and 38,095 ordinary shares at an exercise price of $0.12 per share, expiring on April 20, 2030. His holdings also include multiple restricted stock unit grants that vest quarterly through early 2028 and additional RSUs that vest upon milestone achievements, reflecting a compensation package strongly tied to the company’s long-term performance.
Inspira Technologies OXY B.H.N. Ltd director Tal Parnes filed an initial ownership report showing equity holdings in the company. Parnes directly holds 210,000 ordinary shares, plus share options covering 4,701 ordinary shares at an exercise price of $0.1200 per share, with expiration on April 20, 2030. The position also includes 10,001 restricted stock units vesting quarterly until February 1, 2027 and 100,001 restricted stock units vesting quarterly until February 1, 2028, indicating a mix of current ownership and future potential shares through options and RSUs.
Inspira Technologies OXY B.H.N. Ltd director Matza Sivan filed an initial ownership report showing beneficial ownership of 30,000 ordinary shares. These include 9,999 restricted stock units that vest on October 21, 2026 and 20,001 restricted stock units that vest quarterly from January 21, 2027 until October 21, 2028.
Inspira Technologies OXY B.H.N. Ltd director Amit Lior filed an initial ownership report showing beneficial ownership of 61,667 ordinary shares. This includes 10,001 restricted stock units vesting quarterly until February 1, 2027 and 20,001 restricted stock units vesting quarterly until February 1, 2028, all held directly.